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Abstract
Obesity confers an increased risk of developing specific cancer forms. Although the mechanisms are unclear, increased fat
cell secretion of specific proteins (adipokines) may promote/facilitate development of malignant tumors in obesity via cross-
talk between adipose tissue(s) and the tissues prone to develop cancer among obese. We searched for novel adipokines
that were overexpressed in adipose tissue of obese subjects as well as in tumor cells derived from cancers commonly
associated with obesity. For this purpose expression data from human adipose tissue of obese and non-obese as well as
from a large panel of human cancer cell lines and corresponding primary cells and tissues were explored. We found
expression of ceruloplasmin to be the most enriched in obesity-associated cancer cells. This gene was also significantly up-
regulated in adipose tissue of obese subjects. Ceruloplasmin is the body’s main copper carrier and is involved in
angiogenesis. We demonstrate that ceruloplasmin is a novel adipokine, which is produced and secreted at increased rates in
obesity. In the obese state, adipose tissue contributed markedly (up to 22%) to the total circulating protein level. In
summary, we have through bioinformatic screening identified ceruloplasmin as a novel adipokine with increased expression
in adipose tissue of obese subjects as well as in cells from obesity-associated cancers. Whether there is a causal relationship
between adipose overexpression of ceruloplasmin and cancer development in obesity cannot be answered by these cross-
sectional comparisons.
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Introduction
There is a worldwide increase in obesity prevalence and obesity
and its co-morbidities have become a major health problem in
most countries [1]. Obesity-associated cancer has recently gained
much attention. The World Cancer Research Fund concluded in
2007 that obesity is convincingly associated with increased risk of
pancreatic, (postmenopausal) breast, endometrial and renal cancer
[2]. These conclusions were subsequently confirmed and extended
in a recent meta-analysis of prospective studies assessing cancer
risks associated with $5 kg/m2 increases in body mass index
(BMI) [3]. The strongest risk (odds ratio $1.30) was observed for
renal cancer and oesophagal adenocarcinoma in both genders, for
thyroid cancer in men and for endometrial and gall bladder cancer
in women.
The mechanisms linking obesity to cancer are poorly under-
stood although several theories have been put forward [4,5,6,7,8].
Given that adipose tissue constitutes the body’s largest endocrine
organ, secreting hundreds of peptide signals collectively termed
adipokines, and that adipokine secretion is significantly disturbed
in obesity, an attractive hypothesis is that adipose-derived signals
to other tissues could be involved in cancer development. The two
most thoroughly studied adipokines, adiponectin and leptin, have
in fact been linked to the development of malignant tumors
through their action on cognate receptors affecting insulin
sensitivity and/or activating cancer-associated signaling [4].
Furthermore, several adipokines are growth factors which could
serve as direct signals to tumors [9]. These as well as other, not yet
discovered adipokines, may therefore have cancer-promoting
properties.
In this study, we aimed at finding novel human adipokines that
may be associated with obesity-associated cancers. To this end, we
extracted data from the novel FANTOM5 expression atlas, which
provides an unprecedented coverage of human tissues, primary
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cells and cancer cell lines [10]. We focused on the cancer cell lines
derived from malignant tumors having the strongest association
with obesity (odds ratio $1.3 in either sex) according to Renehan
et al [3]. Putative novel adipokines of potential relevance for
obesity-associated cancers were identified by comparing the
transcriptome enriched in both cancer cells and obese adipose
tissue. This was done by combining the FANTOM5 expression
atlas data with a recently published study of gene expression in
adipose tissue from a large cohort of obese and non-obese women
[11].
This work is part of the FANTOM5 project. Data downloads,
genomic tools and co-published manuscripts are summarized here
http://fantom.gsc.riken.jp/5/.
Methods
Subjects and adipose tissue
All subjects were informed in detail about the study and written
informed consent was obtained. The studies were approved by the
Committee of Ethics at Karolinska Institutet, Stockholm, Sweden.
Three different cohorts of subjects were used in the study. In the
first cohort, described previously [11], subcutaneous adipose tissue
was obtained from 26 non-obese and 30 obese women. Obesity
was defined as BMI 30 kg/m2 or above. RNA was extracted and
subjected to global expression microarray as described [11]. The
gene expression data have been deposited in the National Center
for Biotechnology Gene Expression Omnibus (accession number
GSE25402). The protocol number from the Committee of Ethics
is 592/03 (approved 1st of December 2003).
In the second cohort, subcutaneous adipose tissue was obtained
by cosmetic liposuction and used to experimentally identify novel
adipokines. Nine women were investigated. All were non-obese
and healthy according to self-report. Values (mean 6SD) for age
and BMI were 45613 years and 27.461.2 kg/m2. The tissue was
subjected to collagenase digestion and the stroma-vascular portion
was differentiated into adipocytes in culture as described [11]. For
protein determination in conditioned media, aliquots were
removed 4, 8 and 12 days after the start of differentiation. The
protocol number from the Committee of Ethics is 2009/1881-31/
1 (approved 14th of January 2010).
In the third cohort, adipose tissue secretion of proteins and their
plasma levels were determined. Twenty obese (age 4666 years,
mean6SD) and 19 non-obese healthy women (age 4769 years)
were investigated in the morning after an overnight fast. The obese
were scheduled for bariatric surgery. Seven were healthy, 10 had
hypertension and three had type 2 diabetes treated with oral
agents. Total body fat was determined by dual x-ray absorptiom-
etry (62610 kg in obese and 2468 kg in non-obese). Thereafter, a
venous plasma sample was obtained for determination of
circulating protein levels. Finally, adipose tissue was obtained by
a subcutaneous abdominal biopsy as described [11,12]. Part of the
adipose tissue sample was subjected to in vitro incubation for 2 h
and conditioned medium was used for protein determination as
described [12]. The other part was subjected to collagenase
treatment and isolated fat cells were obtained for the determina-
tion of fat cell size and volume as described [13]. Protein secretion
was related to the number of fat cells in the incubated tissue
sample and to the total amount of body fat. In the latter case,
protein secretion was related to the amount of lipids in the
incubated tissue and this value was multiplied by the total body fat
weight as described [12]. The protocol number from the
Committee of Ethics is 2005/1441-32 (approved 1st of February
2006).
Protein measures
Ceruloplasmin and osteopontin were measured by commercial
ELISA kits (Abcam, Cambridge, UK).
Adipose contribution to total ceruloplasmin production
In order to estimate the contribution of adipose tissue-derived
ceruloplasmin to the circulation, the following assumptions were
made: (a) ceruloplasmin secretion from adipose tissue incubates in
vitro is similar in different adipose regions and reflects in vivo
secretion. (b) ceruloplasmin is evenly distributed in the water space
which is 0.530 l/kg bodyweight in non-obese and 0.465 l/kg
bodyweight in obese subjects [14]. (c) the plasma level of
ceruloplasmin in the morning reflects overall 24 hour levels and
the half-life of the protein is 5.5 days [15]. Based on these
assumptions, total ceruloplasmin production per hour was
estimated as: (measured plasma level x 5.5 x total body water)
divided by 24. Total adipose secretion per hour is measured as
secretion per lipid weight of adipose tissue per hour times total
body fat. From these values the percentage of adipose tissue
contribution to ceruloplasmin production can be calculated.
Cancer and control samples
Based on Renehan et al [3], we identified the following cancer
cell lines in the FANTOM 5 data set as being derived from tumor
types associated to obesity and having an odds ratio$1.30 in men,
women or both. Uterus: endometrial stromal sarcoma cell line
(OMC-9), endometrial carcinoma cell line (OMC-2), endome-
trioid adenocarcinoma cell line (JHUEM-1), clear cell carcinoma
cell line (TEN); Kidney: renal cell carcinoma cell line (OS-RC-2),
renal cell carcinoma cell line (TUHR10TKB); Gall bladder: gall
bladder carcinoma cell line (TGBC2TKB), gall bladder carcinoma
cell line (TGBC14TKB); Thyroid: thyroid carcinoma cell line
(TCO-1), thyroid carcinoma cell line (KHM-5 M), papillary
adenocarcinoma cell line (8505C). As control samples we used
the following tissue and primary cell samples. Uterus: adult and
fetal tissue; Kidney: adult and fetal tissue, Renal Cortical Epithelial
Cells (two donors), Renal Epithelial Cells (three donors), Renal
Glomerular Endothelial Cells (three donors), Renal Mesangial
Cells (three donors), Renal Proximal Tubular Epithelial Cell (three
donors); Gall bladder: adult tissue; Thyroid: adult and fetal tissue.
Identification of novel cancer-related adipokine
candidates
Gene expression in the FANTOM5 database was calculated as
the normalized tag count (tags per million, TPM) in a 1 kb
window around RefSeq [16] transcription start sites. Genes were
identified as candidates if they were expressed at a functionally
significant level (here defined as 10 TPM or higher) and enriched
at least two-fold in the above listed cancer cell lines as compared to
all cell lines available in FANTOM5, while not being enriched
among the corresponding tissues or primary cells. Enrichment was
computed as described in [17] with p-values corrected for multiple
testing using the Benjamini-Hochberg method [18]. Candidate
genes were retained if they were significantly up-regulated at 5%
FDR in the adipose tissue of obese subjects according to a previous
study [11]. Using the FANTOM5 expression database, we
required at least 10 TPM CAGE gene expression across a
receptor locus in one or more obesity associated cancer cell lines
in order to retain it for further investigation.
Adipokines and Obesity Associated Cancer
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Statistical analysis
Values are mean 6 standard error. They were compared by
analysis of variance (repeated measure), unpaired t-test and linear
regression analysis.
Results
Initial analysis of the FANTOM 5 data base [10] and the
published adipose tissue array [11] identified 700 genes which
were significantly expressed ($10 TPM) and at least two-fold
enriched in a cancer cell line of interest but not enriched in the
corresponding tissue or primary cells, and up-regulated in the
adipose tissue of obese. It was not feasible to perform a detailed
analysis of all identified genes or to determine which of them that
were actually secreted from fat cells. Therefore, we further
narrowed the list by restricting expression in the relevant cancer
cell line to $100 TPM (a high expression level), at least five-fold
enrichment in the cancer cell line compared with corresponding
healthy tissue/cell, and at least two-fold up-regulation in adipose
tissue in obesity. Only two genes met these stricter criteria, namely
ceruloplasmin (geneID: CP ) and osteopontin (geneID: SPP1).
Surprisingly, both of them encoded proteins present in the
circulation and were therefore considered potential adipokines.
We investigated whether ceruloplasmin and osteopontin were
actively secreted from fat cells by determining whether there was a
time-dependent release into the media. While osteopontin was not
detectable in the incubation medium (graph not shown), cerulo-
plasmin was indeed released in a time dependent fashion in
differentiating adipocytes (Fig. 1a). Thus, although osteopontin
mRNA is expressed in adipose tissue according to microarray and
is upregulated in obesity [11], the encoded protein does not appear
to be secreted from fat cells implying that osteopontin is not an
adipokine. The influence of obesity on plasma levels and secretion
of ceruloplasmin from subcutaneous adipose tissue was also
investigated (Fig 1b-d). Plasma levels and adipose secretion were
significantly increased in samples from obese subjects. There was a
strong positive relationship between circulating and adipose-
secreted ceruloplasmin. In fact, the latter explained 45% of the
inter-individual variation in plasma ceruloplasmin (adjusted r2),
which was independent of BMI (partial r = 0.36; p = 0.026) or
body fat (partial r = 0.44; p= 0.007). The contribution of adipose
tissue to total ceruloplasmin production was determined as
described in Methods and was estimated to be 1365% in non-
obese and 2266% in obese (p,0.0001).
We further investigated the expression pattern of CP in human
cancer cells. Figure 2 shows the genomic location of CP (Fig 2a, b),
the distribution of promoter activity as measured by cap analysis
gene expression (CAGE, Fig 2c) and CP expression across a wide
panel of cancer cell types sorted by expression level (Fig 2d).
Notably, the cancer cell line with the highest expression of CP is a
clear cell carcinoma from endometrium (Fig 2d, top solid arrow).
Other obesity-associated cancers (renal, endometrial) also display
relatively high CP expression (fig 2d, solid arrows). Hepatic cancer
was not included in this study because it did not meet our criterion
of obesity/cancer association odds ratio of 1.30 or more;
nevertheless it is interesting to note that it is associated with
obesity in men when using slightly less strict criteria (odds
ratio = 1.24 in reference[3]) and that several liver cancer cell lines
Figure 1. Secretion of ceruloplasmin from fat cells. A. Secretion during differentiation of progenitor cells to fat cells. Data are analysed by
ANOVA, repeated measures. B and C. Influence of obesity on plasma levels and secretion from adipose tissue as analyzed with unpaired t-test. D.
Relationship between secreted ceruloplasmin and its plasma levels as analyzed with linear regression.
doi:10.1371/journal.pone.0080274.g001
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are among those with the highest CP expression (fig 2d, broken
arrows). Among the nine cancer cell lines with the highest CP
expression, seven were associated with obesity.
Discussion
In this study we took a systematic approach to identify novel
adipokines that were associated with obesity and obesity-related
cancers by comparing the expression of all obesity-induced genes
in adipose tissue with genes enriched in all cancer cell lines
included in the FANTOM5 study. Using rather stringent selection
criteria, only two genes scored very high in this comparison. In
theory, these genes could have encoded secreted as well as non-
secreted proteins with any type of function. However, it turned out
that both genes encoded circulatory proteins, namely osteopontin
and ceruloplasmin. Osteopontin could not be defined as an
adipokine (protein secreted from fat cells) according to our
findings. In contrast, ceruloplasmin fulfilled the criteria for a true
adipokine, i.e. it is secreted in a time-dependent fashion.
Moreover, since it is not included in the published secretome for
human fat cells, we consider it a novel adipokine [9]. However,
our study cannot establish whether there is a casual relationship
between ceruloplasmin and obesity-associated cancers, and further
studies are needed to determine to what extent, if any,
ceruloplasmin derived from adipocytes or tumor cells plays a
functional role in the growth of cancer tissue. Nevertheless, we can
state that CP is overexpressed in obese adipose tissue and in cancer
cells associated with obesity.
Ceruloplasmin in the circulation is believed to be primarily
produced by the liver [15,19]. However, the present data suggest a
hitherto unknown contributing role of adipose tissue. In line with
earlier findings [20,21], the circulating levels were increased in
obesity. Furthermore, adipose secretion was markedly increased in
obese versus non-obese subjects. Our estimates suggest that
adipose tissue in obesity contributes with up to 22% to the
circulating levels of ceruloplasmin and this secretion explained as
much as 45% of the inter-individual variation in plasma
ceruloplasmin in both non obese and obese subjects. The
relationship between circulating and adipose-secreted ceruloplas-
min was independent of BMI or body fat mass. It should be
stressed that the estimated in vivo values are calculated based on in
vitro results which may be different from those in vivo. Moreover,
the results may be gender biased since the adipose tissue
microarray data used herein was from women while assumptions
on ceruloplasmin distribution were partly based on a previous
study in men [14]. In fact, although we measured ceruloplasmin
secretion in adipose tissue from women, we used male data for
total body water [14] since the latter values were obtained using a
state-of-the-art technique. However, total body water values for
women measured with the less accurate biompedance method are
comparable with those used in our present calculations, namely
0.52760.04, 0.4726.03, and 0.42660.028 l/kg body weight in
lean, overweight and obese females, respectively [22].
Finally, our study examined only subcutaneous adipose tissue.
Since expression and secretion of some adipokines are differen-
tially regulated in different fat depots [23], we do not know
whether ceruloplasmin expressed and released from other depots
Figure 2. View of the ceruloplasmin (CP) locus in the human genome. A. CP is located on on the negative (purple) strand of chromosome 3
at position 3q23-q25, flanked by HPS3 on the positive (green) strand and CPHL1 on the negative strand. B. RefSeq mRNA models of the locus. C.
Promoter activity signal distribution as measured by CAGE in the locus. The majority of expression comes from the 59 end of CP. D. Expression (tags
per million, TPM) across the locus for the cell lines present in FANTOM5. Cell lines with expression above 10 TPM are shown here; in total 269 cell lines
were profiled. Obesity associated cell lines are indicated by black (O.R. .=1.30) and gray (O.R. .=1.20) arrows.
doi:10.1371/journal.pone.0080274.g002
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may display other correlations with obesity. On the other hand,
subcutaneous adipose tissue is by far the body’s largest fat depot
and therefore quantitatively the most important determinant of
circulating adipokine levels.
In summary, by bioinformatically performing a systematic
screening for genes overexpressed in obesity associated cancers,
this study identified ceruloplasmin as a novel human adipokine. Its
secretion and expression are increased in obesity and adipose
ceruloplasmin is a major contributor to the circulating ceruloplas-
min level.
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